Povorcitinib Demonstrates Improvement in Patient-Reported Outcome Measures (PROMs) Evaluating Disease Control and Quality of Life (QOL) in Patients With Chronic Spontaneous Urticaria (CSU)

Weily Soong; Petra Staubach; Jonathan A. Bernstein; Sarbjit S. Saini; Andreas Pinter; Dareen D. Siri; Sophie Biquenet; Michelle Miller; Kofi Wagya; Martin Metz

doi:10.1016/j.jaci.2025.12.012

Povorcitinib Demonstrates Improvement in Patient-Reported Outcome Measures (PROMs) Evaluating Disease Control and Quality of Life (QOL) in Patients With Chronic Spontaneous Urticaria (CSU)

Journal of Allergy and Clinical Immunology 2026

View at publisher

Authors: Weily Soong, Petra Staubach, Jonathan A. Bernstein, Sarbjit S. Saini, Andreas Pinter, Dareen D. Siri, Sophie Biquenet, Michelle Miller, Kofi Wagya, Martin Metz

DOI: 10.1016/j.jaci.2025.12.012

Cited by: 0

Fields of Study & Subjects

Urticaria and Related Conditions Mast cells and histamine Dermatology and Skin Diseases

Publication details

Journal / source: Journal of Allergy and Clinical Immunology
Volume: 157
Issue: 2
Pages: AB2–AB2
Publication date: 1 February 2026
Language: EN